百利達集團控股(08179.HK)供股獲認購約67.00%
格隆匯7月5日丨百利達集團控股(08179.HK)公佈,於2022年6月27日下午四時正,已接獲合共20份有效申請及接納,根據暫定配額通知書及額外申請表格有效接納及申請的1.965億股供股股份合共佔供股項下可供認購供股股份約67.00%。因此,供股認購不足額為9679萬股供股股份,佔供股項下可供認購供股股份約33.00%。
由於包銷協議所載的所有條件已獲達成且包銷協議並無於最後終止時限前被包銷商終止,包銷協議已於2022年6月28日下午四時正成為無條件。
繳足股款供股股份預期於2022年7月7日上午九時正開始於聯交所買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.